U.S. stock market update: Accendra Health's earnings report failed, with stock price plummeting 22.62%, and the debt optimization plan did not boost market confidence

U.S. Stock Market Midday Update Accendra Health fell 22.62%. Based on recent key news: On May 11, Accendra Health released its first-quarter financial report, with net revenue of $627.8 million, below market expectations, leading to a significant drop in stock price. The company reaffirmed its full-year net revenue and adjusted EBITDA guidance. Source: Reuters On May 11, the company announced the initiation of a balance sheet optimization transaction, expected to reduce debt by up to $115 million and extend the debt maturity to 2032 and 2033. This move aims to improve the capital structure, but the market reacted poorly. Source: Reuters On May 12, Accendra's management emphasized the impact of exiting large commercial payer contracts and optimizing the balance sheet. Despite reaffirming full-year performance expectations, the stock price remained under pressure. Source: Reuters The healthcare industry is facing cost pressures, with significant capital outflows. Top Stocks by Industry Trading Volume McKesson rose 0.15%, with increased trading volume. Based on recent key news: On May 9, McKesson announced strong operational performance for fiscal year 2026, reflecting the effectiveness of its growth strategy and the value of its differentiated product portfolio. This news boosted investor confidence and drove the stock price up. On May 9, analysts lowered McKesson's average target price from $997.53 to $962.6; nevertheless, analysts maintained a "Buy" rating. This indicates that the market remains optimistic about the company's long-term prospects. On May 11, MarketBeat's analysis showed that although McKesson was rated as "Moderate Buy," top analysts believe there are five stocks more worthy of purchase than McKesson. This may affect the sentiment of some investors. The pharmaceutical industry is performing steadily overall, with noticeable capital inflows. Cencora rose 0.67%. Cencora rose 0.67%. No significant news recently; trading is active, with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no_news Cardinal Health rose 0.02%. Based on recent news: On May 9, market analysis showed that although Cardinal Health received a moderate buy rating from analysts, top analysts believe there are five stocks with greater investment value. This view may weaken investor confidence in Cardinal Health, affecting stock performance. No other significant news recently. Market analysts are cautious about Cardinal Health. Top Stocks by Industry Market Capitalization Henry Schein rose 0.64%. Based on recent news: On May 11, Henry Schein gained control of S.I.N. 360 U.S. distributors through a transaction, triggering a $11 million remeasurement gain, with diluted earnings per share of approximately $0.07. Management pointed out the potential for further joint venture integrations, but any additional gains are expected to materialize in the second half of 2026 Recently, there are no other important news. Trading volume has increased, and capital flow is evident